Significant transport of doxorubicin into the brain with polysorbate 80- coated nanoparticles

Pharmaceutical Research

Volumn 16, Issue 10, 1999, Pages 1564-1569

  Gulyaev, Alexander E ^a   Gelperina, Svetlana E ^b   Skidan, Igor N ^a   Antropov, Arkady S ^a   Kivman, Gregory Ya ^c   Kreuter, Jörg ^d  

^a KARAGANDA STATE MEDICAL UNIVERSITY   (Kazakhstan)

^b Moscow Research Institute of Medical Ecology   (Russian Federation)

^c Institute of Biotechnology   (Russian Federation)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Brain targeting; Brain tumors; Doxorubicin; Nanoparticles; Polysorbate 80

Indexed keywords

DOXORUBICIN; DRUG CARRIER; NANOPARTICLE; POLY(BUTYL 2 CYANOACRYLATE); POLYSORBATE 80; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG COATING; DRUG DETERMINATION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TRANSPORT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; EXCIPIENTS; HALF-LIFE; INJECTIONS, INTRAVENOUS; MICROSPHERES; POLYSORBATES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0032712180     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018983904537     Document Type: Article

References (30)

1. N. H. Greig. Drug delivery to the brain by blood-brain barrier circumvention and drug modification, in: E. A. Neuwelt (ed.), implications of the Blood-Brain Barrier and Its Manipulation, Plenum Press, New York, 1994, pp. 311-357
2. E. A. Neuwelt P. A. Barnett, K. E. Hellstrom, L. Hellstrom, C. L. McCormick, and F. L. Ramsey. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J. Nucl. Med. 35:1831-1841 (1994).
3. E. Bigon, E. Boarato, A. Bruni, A. Leon, and G. Toffano. Pharmacological effects of phosphatidylserine liposomes: regulation of glycolysis and energy level in brain. Br. J. Pharmacol. 66:167-174 (1979).
4. M. Naoi and K. Yagi. Incorporation of enzyme through blood brain barrier into the brain by means of liposomes. Biochem. Int. 1:591-596 (1980).
5. F. Umezava and Y. Eto. Liposome targeting to mouse brain: Mannose as a recognition marker. Biochem. Biophys. Res. Commun. 153:1038-1044 (1988).
6. W. M. Pardridge. Recent developments in peptide drug delivery to the brain. Pharmacol. Toxicol. 71:3-10 (1992).
7. K. Kakinuma, R. Tanaka, H. Takahashi, M. Watanabe, T. Nakagawa, and M. Kuroki. Targeted chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J. Neurosurg. 84:180-184 (1996).
8. J. Kreuter. Nanoparticles, in: J. Kreuter (ed.), Colloidal Drug Delivery Systems, M. Dekker, New York, 1994, pp. 219-342.
9. P. Couvreur, C. Dubernet, and F. Puisieux. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 41:2-13(1995).
10. J. Kreuter. Evaluation of nanoparticles as drug delivery systems II: Comparison of the body distribution of microspheres (diameter >1 μm), liposomes, and emulsions. Pharm. Acta Helv. 58:217-226 (1983).
11. S. D. Tröster, U. Müller and J. Kreuter. Modification of the body distribution of poly (methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61:85-100 (1990).
12. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer. Biodegradable long-circulating nano-spheres. Science 263:1600-1603 (1994).
13. R. H. Müller. Colloidal Carriers for Controlled Drug Delivery and Targeting. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1991.
14. G. Borchard, K. L. Audus, F. Shi, and J. Kreuter. Uptake of surfactant-coated poly(methylmethacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 110:29-35 (1994).
15. R. N. Alyautdin, D. Gothier, V. Petrov, D. Kharkevich, and J. Kreuter. Analgesic activity of the hexapeptide dalargin absorbed on the surface of polysorbate 80-coated poly(butylcyanocrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41:44-48 (1995).
16. J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:171-174 (1995).
17. P. Couvreur, B. Kante, L. Grislain, M. Roland, and P. Speiser. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71:790-792 (1982).
18. J. Kattan, J. P Droz, P. Couvreur, J. P. Marino, A. Boutan-Larose, P. Rougier, P. Brault, H. Vranckx, G. M. Grognet, X. Morge, and H. Sancho-Garnier. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 10:191-199 (1994).
19. L. G. Alexandrova, A. M. Rubasheva, V. B. Zbarsky, E. L. Salamova, and M. G. Brazhnikova. Quantitative assay of doxorubicin by HPLC technique. Antibiot. Med. Biotechnol (Russia). 11:851-855 (1986).
20. Documenta Geigy, Wissenschaftliche Tabellen, J. R. Geigy A.G. Basel, 7. Aufl., 1968, pp. 174-175.
21. N. Chiannilkulchai, N. Ammoury, B. Caillou, J. P. Devissageut, and P. Couvreur. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastases-bearing mice. Cancer Chemother. Pharmacol. 26:122-126 (1990).
22. P. Couvreur, L. Grislain, V. Lenaerts, F. Brasseur, P. Guiot, and A. Biernacki. Biodegradable polymeric nanoparticles as drug carrier for antitumor agents, in: P. Guiot and P. Couvreur (eds.), Polymeric Nanoparticles and Microsperes, CRC Press, Boca Raton 1986, pp. 27-93.
23. R. N. Alyautdin, V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14:325-328 (1997).
24. R. N Alyautdin, E. B. Tezikov, P. Ramge, D. A. Kharkevich, D. J. Begley, and J. Kreuter. Significant entry of tubocurarin into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. J. Microencapsul. 15:67-74 (1998).
25. J. Kreuter, V. E. Petrov, D. A. Kharkevich, and R. N. Alyautdin. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Contr. Rel. 49:81-87 (1997).
26. W. M. Pardridge. Peptide Drug Delivery to the Brain, Raven Press, New York, 1991, pp. 52-53.
27. D.J. Begley. The interaction of some centrally active drugs with the blood brain barrier and circumventricular organs. Prog. Brain Res. 91:163-169 (1992).
28. C. Cordon-Cardo, J. P. O'Brien, D. Casals, L. Rittmann-Grauer, J. L. Biedler, M. R. Melamed, and J. R. Bertino. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood brain barrier sites. Proc. Natl. Acad. Sci. USA, 86:695-698 (1989).
29. D. M. Woodcock, M. E. Linsenmeyer, G. Chojnowski; A. B. Kriegler, V. Nink, L. K. Webster, and W. H. Sawyer, Reversal of multidrug resistance by surfactants. Br. J. Cancer 66:62-68 (1992).
30. M. M. Nerurkar, P. S. Burto, and R. T. Borchardt. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:528-534 (1996).